The Second Annual Future of Prescription Drug Promotion and Digital Marketing Meeting

The digital transformation of legacy marketing channels combined with emerging and novel digital formats continues the evolution of prescription drug advertising. The U.S. Food and Drug Administration (FDA) is responsible for ensuring that promotional communications for prescription drugs, including direct-to-consumer (DTC) and health care provider (HCP)-directed promotional communications, are truthful, balanced, and accurately communicated. To achieve its mission, it is vital for the FDA to understand the evolving digital marketing landscape, including existing and emerging platforms, strategies, and technologies used by marketers to promote prescription drug products. 

The Duke-Margolis Institute for Health Policy, under a cooperative agreement with the FDA, is convening a second annual virtual workshop that will explore the state of digital prescription drug promotion, including the marketing technologies and strategies currently available and commonly used by marketers, and insights on the future direction of marketing in this space. The objective of this event is to understand how recent and emerging trends in this space may have bearing on public health. Attendees will hear discussion by a range of experts on new formats and strategies that have emerged since the September 2023 convening as well as expansions on discussions from the prior convening.

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U01FD006807 totaling $3,493,089 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.